Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Anemia and immunotherapy].

Thierry Dorval1

  • 1Institut Curie, 26, rue d'Ulm 75248 Paris.

Bulletin Du Cancer
|July 15, 2003
PubMed
Summary
This summary is machine-generated.

Cancer immunotherapy, once abandoned, is revitalized by advances in cytokines and monoclonal antibodies. This report details immunotherapy-induced anemia, a key side effect of modern cancer treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

hsa-miR-548v controls the viscoelastic properties of human cardiomyocytes and improves their relaxation rates.

JCI insight·2024
Same author

A seeding-based neuronal model of tau aggregation for use in drug discovery.

PloS one·2023
Same author

Mathematical modeling of the microtubule detyrosination/tyrosination cycle for cell-based drug screening design.

PLoS computational biology·2022
Same author

IMI European Lead Factory - democratizing access to high-throughput screening.

Nature reviews. Drug discovery·2021
Same author

Development of a chemogenomics library for phenotypic screening.

Journal of cheminformatics·2021
Same author

[From high content screening to target deconvolution: New insights for phenotypic approaches].

Medecine sciences : M/S·2021
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Context:

  • Cancer immunotherapy has a long history, with early non-specific and specific approaches failing to show benefit.
  • Recent advancements in recombinant techniques, tumor antigen identification, and immunology have renewed interest in cancer immunotherapy.
  • Extensive clinical data now exists for cytokine and monoclonal antibody therapies.

Purpose:

  • To review the clinical experience with immunotherapy-induced anemia.
  • To provide insights into the management of anemia associated with modern cancer immunotherapies.

Summary:

  • Early cancer immunotherapy trials were largely unsuccessful and abandoned.
  • Modern immunotherapy leverages cytokines and monoclonal antibodies targeting tumor antigens.

Related Experiment Videos

  • Clinical experience highlights immunotherapy-induced anemia as a significant adverse event.

    • Impact:

    • Understanding immunotherapy-induced anemia is crucial for managing patients undergoing these novel cancer treatments.
    • This review provides valuable information for oncologists and immunologists managing treatment side effects.
    • Informing clinical practice regarding anemia in cancer immunotherapy is essential for patient care.